Abstract
Purpose: Hepatitis C, a chronic disease with deadly consequences, is no longer predominantly a disease of older people. Methods: A limited search was conducted of the relevant literature on 2 topics: (1) the impact of hepatitis C on infants exposed by vertical transmission; and (2) the impact of hepatitis C infection on infected children and adolescents. The findings were supplemented by the first-hand experience of the authors. Findings: Young people, including women of childbearing age, infants, children, and adolescents, are being especially affected by hepatitis C infection secondary to the intravenous drug use and opioid epidemic. Unfortunately, estimates of disease in young populations are all misleading because universal screening has not been implemented. Implications: Lack of implementation of policies for screening and therapy on most affected populations will be responsible for perpetuation of this infection. In the era of highly effective therapy and a regimen that is approved by the US Food and Drug Administration for children, this outcome is unacceptable.
Original language | English (US) |
---|---|
Pages (from-to) | 1299-1307 |
Number of pages | 9 |
Journal | Clinical Therapeutics |
Volume | 40 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2018 |
Funding
Dr. Espinosa has received grant support from Gilead and has participated in clinical trials sponsored by Gilead. Dr. Jhaveri has participated in clinical trials sponsored by Gilead, AbbVie, and Merck and has received grant support from Merck. No industry sponsored or influenced any aspect of this study's design, collection, analysis, or interpretation of the data; writing of the manuscript; or the decision to submit this manuscript for publication.
Keywords
- DAAs
- direct-acting antiviral
- HCV
- hepatitis C virus
- mother-to-child transmission
- MTCT
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)